Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)

Lorent, Marine ; Maalmi, Haïfa ; Tessier, Philippe ; Supiot, Stéphane ; Dantan, Etienne ; Foucher, Yohann

In: BMC Medical Informatics and Decision Making, 19 (2019), Nr. 2. pp. 1-12. ISSN 1472-6947

[thumbnail of 12911_2018_Article_727.pdf]
Preview
PDF, English - main document
Download (1MB) | Lizenz: Creative Commons LizenzvertragMeta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA) by Lorent, Marine ; Maalmi, Haïfa ; Tessier, Philippe ; Supiot, Stéphane ; Dantan, Etienne ; Foucher, Yohann underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: The Cancer of the Prostate Risk Assessment (CAPRA) score was designed and validated several times to predict the biochemical recurrence-free survival after a radical prostatectomy. Our objectives were, first, to study the clinical validity of the CAPRA score, and, second, to assess its clinical utility for stratified medicine from an original patient-centered approach.

Methods: We proposed a meta-analysis based on a literature search using MEDLINE. Observed and predicted biochemical-recurrence-free survivals were compared to assess the calibration of the CAPRA score. Discriminative capacities were evaluated by estimating the summary time-dependent ROC curve. The clinical utility of the CAPRA score was evaluated according to the following stratified decisions: active monitoring for low-risk patients, prostatectomy for intermediate-risk patients, or radio-hormonal therapy for high risk patients. For this purpose, we assessed CAPRA’s clinical utility in terms of its ability to maximize time-dependent utility functions (i.e. Quality-Adjusted Life-Years – QALYs).

Results: We identified 683 manuscripts and finally retained 9 studies. We reported good discriminative capacities with an area under the SROCt curve at 0.73 [95%CI from 0.67 to 0.79], while graphical calibration seemed acceptable. Nevertheless, we also described that the CAPRA score was unable to discriminate between the three medical alternatives, i.e. it did not allow an increase in the number of life years in perfect health (QALYs) of patients with prostate cancer.

Conclusions: We confirmed the prognostic capacities of the CAPRA score. In contrast, we were not able to demonstrate its clinical usefulness for stratified medicine from a patient-centered perspective. Our results also highlighted the confusion between clinical validity and utility. This distinction should be better considered in order to develop predictive tools useful in practice.

Document type: Article
Journal or Publication Title: BMC Medical Informatics and Decision Making
Volume: 19
Number: 2
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 20 Feb 2019 13:15
Date: 2019
ISSN: 1472-6947
Page Range: pp. 1-12
Faculties / Institutes: Service facilities > Netzwerk Alternsforschung
DDC-classification: 610 Medical sciences Medicine
Uncontrolled Keywords: Meta-analysis, Prostate cancer, Patient-centered outcomes, Stratified medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative